Trial document




drksid header

  DRKS00007727

Trial Description

start of 1:1-Block title

Title

Role of Platelets in the progression of Alzheimer's disease

end of 1:1-Block title
start of 1:1-Block acronym

Trial Acronym

Platelets and Alzheimer

end of 1:1-Block acronym
start of 1:1-Block url

URL of the Trial

[---]*

end of 1:1-Block url
start of 1:1-Block public summary

Brief Summary in Lay Language

Histological, cell biological and experiments in the flow cytometer are planned with the respective blood samples.

according to these experiments, basic scientific knowledge should be achieved to understand the impact of platelets in the progression of Alzheimer's disease.

end of 1:1-Block public summary
start of 1:1-Block scientific synopsis

Brief Summary in Scientific Language

Adhesion and aggregation of platelets at the injured vessel wall is essential to avoid excessive blood loss. Dysfunction of platelets is responsible for arterial thrombosis and lung embolism leading to myocardial infarction or stroke.
in the last years it becomes evident that platelets are involved in different cellular processes such as angiogenesis, tumor progression, cell survival and inflammation and play a roel in neuroinflammatory diseases such as Alzheimer's disease.
Alzheimer's disease is characterized by parenchymal and vascular amyloid deposits leading to neuronal loss and cognitive impairment. In addition to brain parenchyma other tissue is affected by Alzheimer's disease such as blood vessels and blood cells leading to alterations in the vasculature and amyloid deposits in the vessel wall, called cerebral Amyloid Angiopathy (CAA). Beside CAA, Alzheimer's disease is strongly associated with cardiovascular diseases e.g. stroke and atheroslcerosis. The main players are platelets that express the amyloid precursor molecule (APP) on their surface and are able to generate Amyloid ß. Therefore platelets were uses as a model system for the analysis of mechanismen relevant in Alzheimer's disease.

Platelets contains high amounts of APP and are the main source of Amyloid ß in blood. Because of CAA different complications are evident in Alzheimer's disease beside neurotoxic consequences, e.g. vessel modifications, hypoperfusion etc.
Therefore the question arises if platelets not only represent relevant mechanisms but are involved in the progression of Alzheimer's disease. To date, the impact of platelets in Alzheimer's disease is not well-defined.

end of 1:1-Block scientific synopsis
start of 1:1-Block organizational data

Organizational Data

  •   DRKS00007727
  •   2015/02/11
  •   [---]*
  •   yes
  •   Approved
  •   4845R, Ethik-Kommission an der Medizinischen Fakultät der Heinrich-Heine-Universität Düsseldorf
end of 1:1-Block organizational data
start of 1:n-Block secondary IDs

Secondary IDs

  • [---]*
end of 1:n-Block secondary IDs
start of 1:N-Block indications

Health Condition or Problem studied

  •   G30 -  Alzheimer disease
  •   F00 -  Dementia in Alzheimer disease
end of 1:N-Block indications
start of 1:N-Block interventions

Interventions/Observational Groups

  •   all patients of the division of Gerontopsychatry,
    LVR Clinic of the Heinrich-Heine university clinic Düsseldorf with diagnosis M. Alzheimer

    Histological, cell biological and flow cytometric experiments are planned using whole blood from Alzheimer's patients. We expect basic scientific knowledge about the role of platelets in M. Alzheimer and the impact of platelets in the progression of the disease.
  •   age-matched healthy volunteers
end of 1:N-Block interventions
start of 1:1-Block design

Characteristics

  •   Non-interventional
  •   Other
  •   Other
  •   Open (masking not used)
  •   [---]*
  •   Other
  •   Basic research/physiological study
  •   Parallel
  •   N/A
  •   N/A
end of 1:1-Block design
start of 1:1-Block primary endpoint

Primary Outcome

Determination of the role of platelets for Alzheimer progression

end of 1:1-Block primary endpoint
start of 1:1-Block secondary endpoint

Secondary Outcome

Scientific goals:

Basic scientific knowledge about differences in patients of different stages concerning hypoperfusion

end of 1:1-Block secondary endpoint
start of 1:n-Block recruitment countries

Countries of Recruitment

  •   Germany
end of 1:n-Block recruitment countries
start of 1:n-Block recruitment locations

Locations of Recruitment

  • University Medical Center 
end of 1:n-Block recruitment locations
start of 1:1-Block recruitment

Recruitment

  •   Planned
  •   2015/03/01
  •   200
  •   Monocenter trial
  •   National
end of 1:1-Block recruitment
start of 1:1-Block inclusion criteria

Inclusion Criteria

  •   Both, male and female
  •   no minimum age
  •   no maximum age
end of 1:1-Block inclusion criteria
start of 1:1-Block inclusion criteria add

Additional Inclusion Criteria

dementia Alzheimer type

end of 1:1-Block inclusion criteria add
start of 1:1-Block exclusion criteria

Exclusion Criteria

dementia other causes

end of 1:1-Block exclusion criteria
start of 1:n-Block addresses

Addresses

  • start of 1:1-Block address primary-sponsor
    • Universitätsklinikum Düsseldorf
    • Moorenstr. 5
    • 40225  Düsseldorf
    • Germany
    end of 1:1-Block address primary-sponsor
    start of 1:1-Block address contact primary-sponsor
    end of 1:1-Block address contact primary-sponsor
  • start of 1:1-Block address other
    • LVR-Klinikum Düsseldorf, Kliniken der Heinrich-Heine-Universität Düsseldorf
    • Mr.  Prof. Dr. med.  Tillmann  Supprian 
    • Bergische Landstr. 2
    • 40629  Düsseldorf
    • Germany
    end of 1:1-Block address other
    start of 1:1-Block address contact other
    end of 1:1-Block address contact other
  • start of 1:1-Block address scientific-contact
    • Universitätsklinikum Düsseldorf, Institut für Hämostaseologie und Transfusionsmedizin
    • Ms.  Univ.-Prof.  Margitta  Elvers 
    • Moorenstr. 5
    • 40225  Düsseldorf
    • Germany
    end of 1:1-Block address scientific-contact
    start of 1:1-Block address contact scientific-contact
    end of 1:1-Block address contact scientific-contact
  • start of 1:1-Block address public-contact
    • Universitätsklinikum Düsseldorf
    • Ms.  Univ.-Prof. Dr.  Margitta  Elvers 
    • Moorenstr. 5
    • 40225  Düsseldorf
    • Germany
    end of 1:1-Block address public-contact
    start of 1:1-Block address contact public-contact
    end of 1:1-Block address contact public-contact
end of 1:n-Block addresses
start of 1:n-Block material support

Sources of Monetary or Material Support

  • start of 1:1-Block address materialSupport
    • Universitätsklinikum Düsseldorf
    • Ms.  Univ.-Prof. Dr.  Margitta  Elvers 
    • Moorenstr. 5
    • 40225  Düsseldorf
    • Germany
    end of 1:1-Block address materialSupport
    start of 1:1-Block address contact materialSupport
    end of 1:1-Block address contact materialSupport
end of 1:n-Block material support
start of 1:1-Block state

Status

  •   Recruiting ongoing
  •   [---]*
end of 1:1-Block state
start of 1:n-Block publications

Trial Publications, Results and other Documents

  • [---]*
end of 1:n-Block publications
* This entry means the parameter is not applicable or has not been set.